UFP Technologies Q1 2026 Earnings Call Summary

1Key Financial Results and Metrics

Revenue Growth: Total revenue increased by 4.1%, driven by a 5.9% rise in medical sales, while non-medical sales fell by 15%.

Earnings Per Share (EPS): Adjusted EPS rose slightly to $2.48.

Gross Margin: Improved to 28.8% from 28.5% year-over-year.

Adjusted Operating Margin: 16.7% of sales.

Cash from Operations: Generated approximately $3.2 million, lower than typical due to high working capital needs.

Debt Management: Paid down approximately $4 million in debt, resulting in a leverage ratio of 1.14x.

SG&A Expenses: Increased by $2.2 million to $21 million, attributed to back-office investments and nonrecurring legal expenses.

2Strategic Updates and Business Highlights

Program Launches: Four simultaneous program launches are underway, with three customers requesting capacity doubling.

Facility Expansion: New buildings are being added in Santiago and La Romana, DR, to support growth in robotic surgery and patient surfaces.

Acquisition Strategy: Actively reviewing multiple acquisition opportunities, with a disciplined approach to valuation and strategic fit.

Management Transition: Mitch Rock is set to take over as CEO in June, with Jeff Bailly remaining as Executive Chair for support.

3Forward Guidance and Outlook

Second Half Expectations: Anticipated acceleration in revenue growth from new programs in the second half of the year.

Medical Segment Growth: Continued focus on expanding medical sales, particularly in robotic surgery and infection prevention.

Non-Medical Business: Expected to remain soft, particularly in automotive, with a gradual phase-out from this market.

4Challenges and Points of Concern

Wound Care Segment: Experienced a decline due to inventory issues with two major customers, expected to impact for about three quarters.

Labor Inefficiencies: Ongoing challenges at AJR due to turnover and inefficiencies, although improvements are being made.

Raw Material Costs: Inflationary pressures from oil prices due to geopolitical tensions, though some tariff relief is anticipated.

5Notable Q&A Insights

Robotics Segment Growth: The 7% growth is primarily from existing programs, with new launches expected to contribute more significantly over time.

Non-Medical Business Outlook: The decline in automotive is seen as a new normal, with some recovery anticipated in aerospace and defense.

M&A Landscape: The market is currently quiet, with a focus on medium-sized acquisitions, which are less prevalent. The company remains disciplined in its approach to potential deals. Overall, UFP Technologies reported a solid start to 2026, with strategic initiatives in place to drive future growth despite facing challenges in certain segments and operational inefficiencies.